Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Senzime AB ( (SE:SEZI) ) has shared an announcement.
Senzime AB announced that its licensee, Fukuda Denshi, has obtained FDA and UKCA approvals to introduce the HN-100 neuromuscular transmission module in the US and UK. This development is significant for Senzime as it expands Fukuda’s market reach, leveraging Senzime’s TetraGraph® technology, and potentially increasing revenue through manufacturing and royalty agreements.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 320,909
Current Market Cap: SEK843.6M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.